Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Baker Tilly Wealth Management LLC

Baker Tilly Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 124.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,155 shares of the biopharmaceutical company's stock after purchasing an additional 641 shares during the period. Baker Tilly Wealth Management LLC's holdings in Regeneron Pharmaceuticals were worth $733,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in REGN. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $28,000. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares in the last quarter. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. Finally, Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:REGN traded down $2.95 during trading on Tuesday, hitting $487.86. 2,139,444 shares of the company were exchanged, compared to its average volume of 843,114. The firm's 50 day moving average price is $581.26 and its 200-day moving average price is $663.80. Regeneron Pharmaceuticals, Inc. has a 12-month low of $481.58 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $52.67 billion, a P/E ratio of 12.74, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the company earned $9.55 EPS. The business's revenue was down 3.7% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.72%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

Several analysts have issued reports on REGN shares. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. TD Cowen dropped their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $700.00 to $580.00 in a research note on Friday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $847.40.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.